A phase 4, open-label exemestane adjuvant safety surveillance program: Adjuvant exemestane (Aromasin) treatment following previous treatment with tamoxifen in postmenopausal women with estrogen sensitive primary breast cancer (IES [Intergroup Exemestane Study] inclusion criteria)
Phase of Trial: Phase IV
Latest Information Update: 28 Sep 2008
At a glance
- Drugs Exemestane (Primary)
- Indications Early breast cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 28 Sep 2008 Actual patient number (1549) added as reported by ClinicalTrials.gov.
- 23 Apr 2008 New trial record.